UniProtKB/Swiss-Prot P07333: Variant p.Pro693His

Macrophage colony-stimulating factor 1 receptor
Gene: CSF1R
Feedback?

Variant information Variant position:

693 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Proline (P) to Histidine (H) at position 693 (P693H, p.Pro693His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (P) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In a lung squamous cell carcinoma sample; somatic mutation. Any additional useful information about the variant.

Sequence information Variant position:

693 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

972 The length of the canonical sequence.
Location on the sequence:

NFLRRKAEAMLGPSLSPGQD P EGGVDYKNIHLEKKYVRRDS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         NFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDS

Mouse                         NFLRRKAEAMLGPSLSPGQDSEGDSSYKNIHLEKKYVRRDS

Rat                           NFLRRKAEAMLGPSLSPGQDSEGDSSYKNIHLEKKYVRRDS

Cat                           NFLRRQAEAMLGPSLSVGQDPEAGAGYKNIHLEKKYVRRDS

Zebrafish                     NFLRSKAENFLNFVMTIPNFPEPMTDYKNVSTERMFVRSDS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	20 – 972	Macrophage colony-stimulating factor 1 receptor
Topological domain	539 – 972	Cytoplasmic
Domain	582 – 910	Protein kinase
Modified residue	699 – 699	Phosphotyrosine; by autocatalysis
Modified residue	708 – 708	Phosphotyrosine; by autocatalysis
Modified residue	713 – 713	Phosphoserine
Alternative sequence	307 – 972	Missing. In isoform 2.
Mutagenesis	708 – 708	Y -> F. Impairs degradation of activated CSF1R.

Literature citations
Patterns of somatic mutation in human cancer genomes.
Greenman C.; Stephens P.; Smith R.; Dalgliesh G.L.; Hunter C.; Bignell G.; Davies H.; Teague J.; Butler A.; Stevens C.; Edkins S.; O'Meara S.; Vastrik I.; Schmidt E.E.; Avis T.; Barthorpe S.; Bhamra G.; Buck G.; Choudhury B.; Clements J.; Cole J.; Dicks E.; Forbes S.; Gray K.; Halliday K.; Harrison R.; Hills K.; Hinton J.; Jenkinson A.; Jones D.; Menzies A.; Mironenko T.; Perry J.; Raine K.; Richardson D.; Shepherd R.; Small A.; Tofts C.; Varian J.; Webb T.; West S.; Widaa S.; Yates A.; Cahill D.P.; Louis D.N.; Goldstraw P.; Nicholson A.G.; Brasseur F.; Looijenga L.; Weber B.L.; Chiew Y.-E.; DeFazio A.; Greaves M.F.; Green A.R.; Campbell P.; Birney E.; Easton D.F.; Chenevix-Trench G.; Tan M.-H.; Khoo S.K.; Teh B.T.; Yuen S.T.; Leung S.Y.; Wooster R.; Futreal P.A.; Stratton M.R.;
Nature 446:153-158(2007)
Cited for: VARIANTS [LARGE SCALE ANALYSIS] GLY-32; ARG-362; SER-413; VAL-536; HIS-693; ASP-920 AND GLN-921;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.